JPRN-UMIN000044038已完成未知
An Open-Label, Expanded Access Program with Nivolumab (ONO-4538) for cancer of unknown primary (CUP) (NivoCUP-2) Biomarker study (WJOG14620MTR) - WJOG14620MTR
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
ivoCUP-2JPRN-jRCT2051200146akagawa Kazuhiko60
已完成
Unknown
An Open-Label, Expanded Access Program With Lenvatinib for the First Line Treatment of Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaJPRN-jRCT2080223705Eisai Co., Ltd.30
已完成
2 期
An Open-Label, Non-Comparative Expanded Access Study of the Raf-Kinase Inhibitor Sorafenib as a Subsequent to First-Line Therapy in Patients with Advanced Renal Cell CarcinomaAdvanced renal cell carcinomaCancer - Renal Cell CarcinomaACTRN12606000140550Austin Health75
已完成
Unknown
Trastuzumab deruxtecan for subjects with HER2 mutated metastatic NSCLCJPRN-jRCT2071220096eno Shizuko30
进行中（未招募）
1 期
Clinical Study with the bispecific antibody Blinatumomab in pediatric and adolescent subjects with B-precursor Acute Lymphoblastic Leukemia (ALL) who did not respond to previous therapy or who relapsed after initial successful previous therapyEUCTR2014-001700-21-DEAmgen Inc.100